KR100880371B1 - Cns 장애의 치료를 위한 tgf-r 시그널화 억제제 - Google Patents
Cns 장애의 치료를 위한 tgf-r 시그널화 억제제 Download PDFInfo
- Publication number
- KR100880371B1 KR100880371B1 KR1020067018097A KR20067018097A KR100880371B1 KR 100880371 B1 KR100880371 B1 KR 100880371B1 KR 1020067018097 A KR1020067018097 A KR 1020067018097A KR 20067018097 A KR20067018097 A KR 20067018097A KR 100880371 B1 KR100880371 B1 KR 100880371B1
- Authority
- KR
- South Korea
- Prior art keywords
- tgf
- disease
- seq
- disorders
- degeneration
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
Abstract
Description
Claims (28)
- 삭제
- 삭제
- 삭제
- 서열 번호 3 및 하기 서열식으로 나타낼 수 있는 서열 번호 3의 신장된 서열을 포함하는 군 중에서 선택되는 하나 이상의 올리고뉴클레오티드 또는 상기 올리고뉴클레오티드를 전사시킬 수 있는 벡터와, 하나 이상의 제약학적으로 허용되는 담체, 부형제 또는 희석제를 함께 포함하는 CNS 질환 치료용 제약학적 제제:상기 서열 번호 3의 신장된 서열은 다음과 같다:5'-XCAGCCCCCGACCCATGZ-3'상기 식에서, X는 하기 올리고뉴클레오티드를 포함하는 군으로부터 선택되고:ACAGGACGATGTGCAGCGGCCACAGGCCCCTGAG, CAGGACGATGTGCAGCGGCCACAGGCCCCTGAG, AGGACGATGTGCAGCGGCCACAGGCCCCTGAG, GGACGATGTGCAGCGGCCACAGGCCCCTGAG, GACGATGTGCAGCGGCCACAGGCCCCTGAG, ACGATGTGCAGCGGCCACAGGCCCCTGAG, CGATGTGCAGCGGCCACAGGCCCCTGAG, GATGTGCAGCGGCCACAGGCCCCTGAG, ATGTGCAGCGGCCACAGGCCCCTGAG, TGTGCAGCGGCCACAGGCCCCTGAG, GTGCAGCGGCCACAGGCCCCTGAG, TGCAGCGGCCACAGGCCCCTGAG, GCAGCGGCCACAGGCCCCTGAG, CAGCGGCCACAGGCCCCTGAG, AGCGGCCACAGGCCCCTGAG, GCGGCCACAGGCCCCTGAG, CGGCCACAGGCCCCTGAG, GGCCACAGGCCCCTGAG, GCCACAGGCCCCTGAG, CCACAGGCCCCTGAG, CACAGGCCCCTGAG, ACAGGCCCCTGAG, CAGGCCCCTGAG, AGGCCCCTGAG, GGCCCCTGAG, GCCCCTGAG, CCCCTGAG, CCCTGAG, CCTGAG, CTGAG, TGAG, GAG, AG, G;Z는 하기 올리고뉴클레오티드를 포함하는 군으로부터 선택되며:GCAGACCCCGCTGCTCGTCATAGACCGAGCCCCC, GCAGACCCCGCTGCTCGTCATAGACCGAGCCCC, GCAGACCCCGCTGCTCGTCATAGACCGAGCCC, GCAGACCCCGCTGCTCGTCATAGACCGAGCC, GCAGACCCCGCTGCTCGTCATAGACCGAGC, GCAGACCCCGCTGCTCGTCATAGACCGAG, GCAGACCCCGCTGCTCGTCATAGACCGA, GCAGACCCCGCTGCTCGTCATAGACCG, GCAGACCCCGCTGCTCGTCATAGACC, GCAGACCCCGCTGCTCGTCATAGAC, GCAGACCCCGCTGCTCGTCATAGA, GCAGACCCCGCTGCTCGTCATAG, GCAGACCCCGCTGCTCGTCATA, GCAGACCCCGCTGCTCGTCAT, GCAGACCCCGCTGCTCGTCA, GCAGACCCCGCTGCTCGTC, GCAGACCCCGCTGCTCGT, GCAGACCCCGCTGCTCG, GCAGACCCCGCTGCTC, GCAGACCCCGCTGCT, GCAGACCCCGCTGC, GCAGACCCCGCTG, GCAGACCCCGCT, GCAGACCCCGC, GCAGACCCCG, GCAGACCCC, GCAGACCC, GCAGACC, GCAGAC, GCAGA, GCAG, GCA, GC, G;X 및 Z는 함께 34개 이하의 뉴클레오티드 염기를 포함하고;상기 올리고뉴클레오티드는 TGF-RII을 암호화하는 유전자의 개방 판독 프레임(Open Reading Frame)의 해독 개시 또는 종결 코돈에 하이브리드화할 수 있지만,단, 상기 올리고뉴클레오티드는 서열 5'-CAGCCCCCGACCCATGGCAG-3'이 아니다.
- 제 4항에 있어서, 상기 제약학적 제제가 활성 성분의 연속 방출을 위한 주입 용액 또는 고형 매트릭스인 CNS 질환 치료용 제약학적 제제.
- 제 4항에 있어서, 상기 제약학적 제제가 뇌로의 국부 투여에 적합한 CNS 질환 치료용 제약학적 제제.
- 손상된 신경 통로의 성공적인 재생 및 기능 재개를 촉진하기 위한 것으로서, 제 4항에 따른 하나 이상의 올리고뉴클레오티드를 포함하는 CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 손상된 신경 통로의 성공적인 재생 및 기능 재개를 촉진하기 위한 것으로서, 하나 이상의 제 7항에 따른 올리고뉴클레오티드, 상기 올리고뉴클레오티드를 전사시킬 수 있는 벡터, 또는 제 7항에 따른 하나 이상의 올리고뉴클레오티드를 포함하는 제약학적 제제를 포함하는 CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 신경퇴행성 장애, 외상/외상후 장애, 혈관/저산소증 장애, 신경염증 및 감염후 중추 신경계 장애 및 뉴론 줄기 세포 재생의 나이 유발된 감소의 예방, 치료적 방지 및 치료를 위한 것으로서, 하나 이상의 제 8항에 따른 올리고뉴클레오티드, 상기 올리고뉴클레오티드를 전사시킬 수 있는 벡터, 또는 제 7항에 따른 하나 이상의 올리고뉴클레오티드를 포함하는 제약학적 제제를 포함하는 CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 제 9항에 있어서, 상향-조절되거나 향상된 TGF-RII 수준과 관련된 질환에서 TGF-RII 발현을 억제하기 위한, CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 제 9항에 있어서, 상향-조절되거나 향상된 TGF-RII 수준과 관련된 질환 또는 신경퇴행성 장애 및 신경염증 장애가 알츠하이머 질환, 파킨슨 질환, 크로이츠펠트-야콥 질환 (CJD), 크로이츠펠트-야콥 질환의 신변이 질환 (nvCJD), 할러포르텐-스파츠 질환 (Hallervorden Spatz disease), 헌팅톤 질환, 다체계 위축증, 치매, 프론템포랄 치매, 근위축성 측삭 경화증, 척수성 근위축증, 척수소뇌 위축증 (SCA), 또는 기타 운동 뉴론 장애, 정신분열증, 정동 장애, 주요 우울증, 수막뇌염, 세균성 수막뇌염, 바이러스성 수막뇌염, CNS 자가면역 장애, 다발성 경화증 (MS), 급성 허혈/저산소성 상해, 발작, CNS 및 척수 외상, 머리 및 척수 외상, 동맥경화증, 아테롬성 동맥경화증, 미소혈관장애성 치매, 빈스방거 질환 (Binswanger' disease) (류코아라이오시스: Leukoaraiosis), 망막 변성, 와우 변성 (cochlear degeneration), 황반 변성, 와우 청각소실증, AIDS-연관 치매, 망막세포변성, 취약 X-관련 실조/진전 증후군 (FXTAS), 진행성 핵상성 마비 (PSP), 선조체 흑질 변성 (SND), 올리브뇌교소뇌 변성 (olivopontocerebellear degeneration: OPCD), 샤이 드래거 증후군 (Shy Drager syndrome: SDS), 나이 의존적 기억 장애, 치매와 연관된 신경발달 장애, 다운 증후군, 시뉴클레이노패씨 (synucleinopathies), 슈퍼옥사이드 디스뮤타제 돌연변이, 트리뉴클레오티드 반복 장애, 외상, 저산소증, 혈관 질환, 혈관 염증, CNS-노화로 이루어진 군 중에서 선택되는, CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 제 9항에 있어서, TGF-RII의 상향-조절되거나 향상된 시그널화(signaling)와 관련된 질환에서 TGF-β 활성을 억제하기 위한, CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- 제 9항에 있어서, TGF-RII의 상향-조절되거나 향상된 시그널화와 관련된 질환 또는 신경퇴행성 장애 및 신경염증 장애가 알츠하이머 질환, 파킨슨 질환, 크로이츠펠트-야콥 질환 (CJD), 크로이츠펠트-야콥 질환의 신변이 질환 (nvCJD), 할러포르텐-스파츠 질환, 헌팅톤 질환, 다체계 위축증, 치매, 프론템포랄 치매, 근위축성 측삭 경화증, 척수성 근위축증, 척수소뇌 위축증 (SCA), 또는 기타 운동 뉴론 장애, 정신분열증, 정동 장애, 주요 우울증, 수막뇌염, 세균성 수막뇌염, 바이러스성 수막뇌염, CNS 자가면역 장애, 다발성 경화증 (MS), 급성 허혈/저산소성 상해, 발작, CNS 및 척수 외상, 머리 및 척수 외상, 동맥경화증, 아테롬성 동맥경화증, 미소혈관장애성 치매, 빈스방거 질환 (류코아라이오시스), 망막 변성, 와우 변성, 황반변성, 와우청각소실증, AIDS-연관 치매, 망막세포변성, 취약 X-관련 실조/진전 증후군 (FXTAS), 진행성 핵상성 마비 (PSP), 선조체 흑질 변성 (SND), 올리브뇌교소뇌 변성 (OPCD), 샤이 드래거 증후군 (SDS), 나이 의존적 기억 장애, 치매와 연관된 신경발달 장애, 다운 증후군, 시뉴클레이노패씨, 슈퍼옥사이드 디스뮤타제 돌연변이, 트리뉴클레오티드 반복 장애, 외상, 저산소증, 혈관 질환, 혈관 염증, CNS-노화로 이루어진 군 중에서 선택되는, CNS 질환 치료를 위한 TGF-R 시그널화 억제제.
- (a) 후보 화합물을 TGF-β1 및 뉴론 전구 세포를 포함하는 시험계와 함께 인큐베이션하는 단계; 및(b) 활성 TGF 수용체의 발현 또는 뉴론 전구 세포의 증식을 검정하는 단계를 포함하는 방법으로서, 이때(c) 상기 시험 화합물의 부재 하에서의 시험 시스템과 비교하여 (i) 활성 TGF 수용체의 발현의 저해 또는 (ii) 뉴론 전구 세포의 증식 저해의 제거가 목적하는 특성을 갖는 후보 화합물이 존재한다는 것을 나타내는 것임을 특징으로 하는, (1) TGF-RII의 생물학적 활성 또는 TGF-RII의 발현 또는 (2) TGF-β1/TGF-R 시그널화를 방해하는 화합물을 확인하는 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04002846 | 2004-02-09 | ||
EP04002846.6 | 2004-02-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070004695A KR20070004695A (ko) | 2007-01-09 |
KR100880371B1 true KR100880371B1 (ko) | 2009-01-30 |
Family
ID=34833578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067018097A KR100880371B1 (ko) | 2004-02-09 | 2005-02-09 | Cns 장애의 치료를 위한 tgf-r 시그널화 억제제 |
Country Status (16)
Country | Link |
---|---|
US (2) | US8022045B1 (ko) |
EP (1) | EP1716235B1 (ko) |
JP (2) | JP4712728B2 (ko) |
KR (1) | KR100880371B1 (ko) |
CN (1) | CN1989244B (ko) |
AU (1) | AU2005210151B2 (ko) |
BR (1) | BRPI0507528A (ko) |
CA (1) | CA2555463C (ko) |
ES (1) | ES2387593T3 (ko) |
IL (1) | IL177320A (ko) |
MX (1) | MXPA06008964A (ko) |
NZ (1) | NZ548926A (ko) |
PL (1) | PL1716235T3 (ko) |
RU (1) | RU2385933C2 (ko) |
WO (1) | WO2005074981A2 (ko) |
ZA (1) | ZA200606460B (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109546A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof |
WO2009146301A1 (en) | 2008-05-27 | 2009-12-03 | Yale University | TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE |
JP2011236128A (ja) * | 2008-09-01 | 2011-11-24 | Osaka Univ | 中枢神経損傷治療剤 |
KR20110115589A (ko) * | 2009-01-24 | 2011-10-21 | 파이토팜 피엘씨 | 신경영양인자가 매개된 장애의 치료 |
KR101661847B1 (ko) * | 2014-03-18 | 2016-09-30 | 사회복지법인 삼성생명공익재단 | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 |
CN104004762B (zh) * | 2014-05-20 | 2016-03-30 | 南京医科大学附属南京儿童医院 | Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用 |
EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
CA2982105A1 (en) | 2015-04-07 | 2016-10-13 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods for inducing cell division of postmitotic cells |
WO2019140231A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
CN110548132B (zh) * | 2019-10-24 | 2023-04-25 | 安徽医科大学附属巢湖医院 | TGF-β1蛋白在制备治疗抑郁症的药物中的应用 |
CN114854738A (zh) * | 2021-02-04 | 2022-08-05 | 纳肽得(青岛)生物医药有限公司 | 用于治疗与TGFβ1表达相关的疾病的siRNA |
WO2023039345A2 (en) * | 2021-09-12 | 2023-03-16 | Oncotelic, Inc. | Treatment of neurological disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000656A2 (en) * | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of transforming growth factor beta receptor ii expression |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3943793A (en) * | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
KR100342942B1 (ko) | 1999-07-05 | 2002-07-02 | 민경윤 | 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물 |
CA2381006A1 (en) | 1999-09-17 | 2001-03-22 | Nicholas M. Dean | Antisense modulation of transforming growth factor-.beta. expression |
EP1133988A1 (en) * | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
KR20030056538A (ko) | 2001-12-28 | 2003-07-04 | 주식회사 웰진 | 리본형 안티센스 올리고뉴클레오티드에 의한 형질전이성장 인자-β1의 효과적 저해제 개발 |
EP1590467B1 (en) | 2003-01-28 | 2009-10-21 | Ludwig Aigner | Use of regulatory sequences for specific, transient expression in neuronal determined cells |
-
2005
- 2005-02-09 RU RU2006129326/13A patent/RU2385933C2/ru not_active IP Right Cessation
- 2005-02-09 KR KR1020067018097A patent/KR100880371B1/ko not_active IP Right Cessation
- 2005-02-09 BR BRPI0507528-9A patent/BRPI0507528A/pt not_active Application Discontinuation
- 2005-02-09 NZ NZ548926A patent/NZ548926A/xx not_active IP Right Cessation
- 2005-02-09 PL PL05707286T patent/PL1716235T3/pl unknown
- 2005-02-09 JP JP2006551825A patent/JP4712728B2/ja not_active Expired - Fee Related
- 2005-02-09 CN CN2005800098901A patent/CN1989244B/zh not_active Expired - Fee Related
- 2005-02-09 CA CA2555463A patent/CA2555463C/en not_active Expired - Fee Related
- 2005-02-09 ES ES05707286T patent/ES2387593T3/es active Active
- 2005-02-09 EP EP05707286A patent/EP1716235B1/en not_active Not-in-force
- 2005-02-09 AU AU2005210151A patent/AU2005210151B2/en not_active Ceased
- 2005-02-09 US US10/597,813 patent/US8022045B1/en not_active Expired - Fee Related
- 2005-02-09 MX MXPA06008964A patent/MXPA06008964A/es active IP Right Grant
- 2005-02-09 WO PCT/EP2005/001298 patent/WO2005074981A2/en active Application Filing
- 2005-02-09 ZA ZA200606460A patent/ZA200606460B/en unknown
-
2006
- 2006-08-07 IL IL177320A patent/IL177320A/en not_active IP Right Cessation
-
2010
- 2010-09-10 JP JP2010203733A patent/JP4848042B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-15 US US13/028,035 patent/US8283334B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000656A2 (en) * | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of transforming growth factor beta receptor ii expression |
Also Published As
Publication number | Publication date |
---|---|
NZ548926A (en) | 2009-07-31 |
IL177320A (en) | 2012-03-29 |
MXPA06008964A (es) | 2007-02-02 |
JP4712728B2 (ja) | 2011-06-29 |
AU2005210151A1 (en) | 2005-08-18 |
WO2005074981A8 (en) | 2010-04-15 |
WO2005074981A2 (en) | 2005-08-18 |
JP4848042B2 (ja) | 2011-12-28 |
RU2006129326A (ru) | 2008-03-20 |
EP1716235B1 (en) | 2012-06-06 |
KR20070004695A (ko) | 2007-01-09 |
ES2387593T3 (es) | 2012-09-26 |
US20110263678A1 (en) | 2011-10-27 |
ZA200606460B (en) | 2008-02-27 |
CN1989244B (zh) | 2013-04-03 |
PL1716235T3 (pl) | 2012-11-30 |
CA2555463C (en) | 2013-05-14 |
AU2005210151B2 (en) | 2010-07-01 |
IL177320A0 (en) | 2006-12-10 |
RU2385933C2 (ru) | 2010-04-10 |
JP2011021023A (ja) | 2011-02-03 |
US8022045B1 (en) | 2011-09-20 |
BRPI0507528A (pt) | 2007-07-03 |
JP2007521815A (ja) | 2007-08-09 |
WO2005074981A3 (en) | 2006-01-12 |
CN1989244A (zh) | 2007-06-27 |
EP1716235A2 (en) | 2006-11-02 |
US8283334B2 (en) | 2012-10-09 |
CA2555463A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100880371B1 (ko) | Cns 장애의 치료를 위한 tgf-r 시그널화 억제제 | |
AU2020203573B2 (en) | Oligonucleotides for inducing paternal UBE3A expression | |
KR102318434B1 (ko) | 병태 및 질환 치료용 안티센스 올리고머 | |
AU2017200759B2 (en) | Modulation of androgen receptor expression | |
KR102149571B1 (ko) | 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법 | |
AU2018203564A1 (en) | Antisense modulation of gccr expression | |
KR20210025055A (ko) | Lrrk2 발현 감소용 화합물 및 방법 | |
CN112080502A (zh) | 用于调节c9orf72表达的组合物 | |
CN114058617A (zh) | 缀合反义化合物及其用途 | |
KR20120099363A (ko) | 탯줄 혈액으로부터의 유도 만능 줄기 세포의 생성 | |
KR20220113743A (ko) | 병태 및 질환의 치료를 위한 안티센스 올리고머 | |
DK2809400T3 (en) | COMBINATION THERAPY INCLUDING A GROWTH HORMON VARIANT AND AN OIGONUCLEOTIDE BINDING TO THE GROWTH HORMON RECEPTOR | |
KR20210065125A (ko) | 인간의 앤젤만 증후군에서 부계 ube3a 유전자 발현을 복원하기 위한 조성물 및 방법 | |
TW202221014A (zh) | 用於減少app表現之化合物及方法 | |
CN116157522A (zh) | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 | |
CA2474759A1 (en) | Gene for peripheral arterial occlusive disease | |
KR20230005933A (ko) | Atxn1을 조정하는 화합물 및 방법 | |
CN111344408A (zh) | 用于调控fndc3b表达的寡核苷酸 | |
RU2773197C2 (ru) | Антисмысловые олигонуклеотиды к альфа-синуклеину и их применения | |
US20030039968A1 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
TW202305132A (zh) | 用於抑制α-突觸核蛋白表達之反義寡核苷酸 | |
CN110559440A (zh) | 靶向cdc40基因核苷酸序列的活性物质在制备治疗肝病药物中的用途 | |
KR20230095056A (ko) | Scn2a에서 기능-상실 돌연변이와 연관된 장애를 치료하기 위한 조성물 및 방법 | |
US20030224393A1 (en) | Gene for peripheral arterial occlusive disease | |
CN111556894A (zh) | 用于调控gsk3b表达的寡核苷酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121120 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131203 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160114 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170110 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180213 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |